NCT00509379已完成2 期
A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie22 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 22
- 主要终点
- To demonstrate a statistical benefit in overall response rate (ORR) of the Bortezomib/Rituximab association in this study 3/13 or fewer responses are observed during the first stage then the trail is stopped early
研究概览
简要总结
The promising activity of Bortezomib as single agent in low grade lymphoma patients in small studies has led to a number of larger multicenter trials with Bortezomib in combination with Rituximab in mantle-cell lymphoma, follicular lymphoma and marginal zone lymphoma.
详细描述
This is a open label, non randomized, phase II , multicenter, prospective trial to evaluate the efficacy and safety of the combination of bortezomib and rituximab in patients with relapsed or refractory rituximab naïve or sensitive indolent non-follicular and mantle cell non-Hodgkin's lymphoma. Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis of relapsed indolent lymphoma. This study is designed for patients not eligible for high-dose chemotherapy and autologous stem cells transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with naïve or sensitive rituximab indolent non-follicular and mantle cell non-Hodgkin's Lymphoma disease that had failed to respond or relapsed after primary therapy. There is a demonstrated progressive disease requiring further treatment. Histological subtype included into the study are are as follows Small lymphocytic/lymphoplasmocytic lymphoma; Nodal marginal zone Lymphoma (MALT lymphoma are excluded) Splenic marginal zone lymphoma Mantle cell lymphoma A lymphnode biopsy is advisable if it is not harmful for the patients, before enrollment of the patient into the study in order to confirm diagnosis and to rule out histologic transformation. Lymphnode biopsy should be performed within 6 months before study entry.
- •Age >18-75
- •Relapse or failure to respond after one or more (maximum three) lines of chemotherapy
- •Any type of prior chemotherapy, rituximab included. Patients who had received high dose chemotherapy and ASCT can be enrolled into the study
- •Naïve or sensitive rituximab disease. If the patient received Rituximab, he/she must have responded and the TTP from the last dose to rituximab must have been 6 months or more.
- •Measurable and/or evaluable disease.
- •Adequate haematological counts: ANC> 1.0 x 109/L and PLT counts> 75 x 109/L unless due to bone marrow involvement by lymphoma.
- •Conjugated bilirubin up to 2 x ULN.
- •Alkaline phosphatase and transaminases up to 2 x ULN.
- •Creatinine clearances> 30 m/min.
- •Non peripheral neuropathy or CNS disease.
- •Life expectancy> 6 months.
- •Performance status< 2 according to ECOG scale.
- •Written informed Consent
排除标准
- •Has known or suspected hypersensitivity or intolerance to rituximab, boron, mannitol, or heparin, if an indwelling catheter is used
- •History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
- •Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
- •Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
- •History of hypotension or has decreased blood pressure (sitting systolic blood pressure SBP 100 mmHg and/or sitting diastolic blood pressure DBP 60 mmHg)
- •Pregnant or breastfeeding
- •Peripheral Neuropathy or Neuropathic Pain Grade 2
- •HIV positivity
- •HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
- •HCV positivity with the exception of patients with no signs of active chronic hepatitis histologically confirmed
- •Active opportunistic infection
- •Receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrollment
- •Exposure to Rituximab within 24 weeks before screening
- •Have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
- •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
研究组 & 干预措施
1
Experimental
All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
干预措施: Rituximab (Drug)
1
Experimental
All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
干预措施: VELCADE (Drug)
结局指标
主要结局
To demonstrate a statistical benefit in overall response rate (ORR) of the Bortezomib/Rituximab association in this study 3/13 or fewer responses are observed during the first stage then the trail is stopped early
时间窗: 1 year
次要结局
- If 12/43 or fewer responses are observed by the end of the trail, then no further investigation of this regimen is warranted(4 years)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Bortezomib in Treating Patients With Lymphoproliferative DisordersRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaNCT00023764National Cancer Institute (NCI)103
已完成
2 期
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00547534University of Rochester31
进行中（未招募）
不适用
Comparison of two strategies to treat refractory or relapsed Multiple Myeloma. All patients receive Bortezomib and Dexamethasone, one half receives additional Cyclophosphamide.Refractory or relapsed multiple myeloma after 1 to 3 previous lines of therapy, including high-dose therapyMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003213-27-DEORTHO BIOTECH, Division of JANSSEN-CILAG GmbH
进行中（未招募）
不适用
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiplemyelomaKCT0004508Samsung Medical Center126
进行中（未招募）
不适用
A PHASE II MULTICENTER STUDY OF BORTEZOMIB, THALIDOMIDE, PEGHILATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE (ThaDD-V)IN PATIENTS AFFECTED BY RELAPSED-REFRACTORY MULTIPLE MYELOMA - NDEUCTR2006-002564-25-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI